Bulletin from the Extraordinary General Meeting of Chordate Medical Holding AB (publ)

At the Extraordinary General Meeting of Chordate Medical Holding AB (publ), held on December 8, 2025, the following resolution was passed. All resolutions were adopted in accordance with the proposals previously made public in the notice to attend the meeting.

Resolution on liquidation
The General Meeting resolved, in accordance with the Board of Directors’ proposal, that the Company shall enter into voluntary liquidation pursuant to Chapter 25, Section 3 of the Swedish Companies Act.

Attorney Lars-Olof Svensson, CMS Wistrand Advokatbyrå, was appointed liquidator.

The liquidation will enter into force when the Swedish Companies Registration Office has formally appointed the liquidator.

Resolution on delisting from Nasdaq First North Growth Market
The General Meeting resolved, in accordance with the Board of Directors’ proposal, that the shares of Chordate Medical Holding AB (publ) shall be delisted from Nasdaq First North Growth Market pursuant to item II.1.B of the Rules on Delisting at the Initiative of the Issuer issued by the Swedish Securities Council’s Self-Regulation Committee.

It was noted that the resolution on delisting was supported by shareholders representing all (100 per cent) of both the votes cast and the shares represented at the General Meeting.

More press releases

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact